Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera
© Batra et al; licensee BioMed Central Ltd. 2011
Received: 25 August 2010
Accepted: 15 March 2011
Published: 15 March 2011
Flavivirus cross-reactive antibodies in human sera interfere with the definitive identification of dengue virus (DENV) infections especially in areas with multiple co-circulating flaviviruses. Use of DENV envelope domain-III (EDIII) can partially resolve the problem. This study has examined the effect of (i) incorporating the EDIIIs of four DENV serotypes into a single chimeric antigen, and (ii) immobilizing the antigen through specific interaction on the sensitivity and specificity of anti-DENV antibody detection.
A sera panel (n = 164) was assembled and characterized using commercial kits for infection by DENV and a host of other pathogens. Anti-DENV antibodies of both IgM and IgG classes in this panel were detected in indirect ELISAs using a mixture of monovalent EDIIIs, a chimeric EDIII-based tetravalent antigen, EDIII-T, and a biotinylated version of the latter as coating antigens. The sensitivity and specificity of these assays were compared to those obtained using the PanBio Dengue IgG/IgM ELISAs.
The performance of dengue IgG and IgM indirect ELISAs, using either a physical mixture of four EDIIIs or the single chimeric EDIII-T antigen, were comparable. Coating of a biotinylated version of the tetravalent antigen on streptavidin plates enhanced sensitivity without compromising specificity.
The incorporation of the EDIIIs of the four DENV serotypes into a single chimeric antigen did not adversely affect assay outcome in indirect ELISAs. Oriented, rather than random, immobilization of the tetravalent antigen enhanced sensitivity of detection of anti-DENV antibodies with retention of 100% specificity.
Dengue viruses (DENV), of which there are four serotypes (DENV-1,-2,-3 and -4), are mosquito-borne flaviviruses of the Flaviviridae family, which also includes other members, such as yellow fever virus, Japanese encephalitis virus, West Nile virus and tick-borne encephalitis virus (TBEV) . Currently, there is no vaccine to prevent or a drug to treat DENV infection, which poses a public health threat to nearly half the global population . In this scenario, the availability of reliable diagnostic tools assumes great importance in clinical management, surveillance and outbreak investigations. As DENVs share antigenic similarities with other flaviviruses and tend to co-circulate with some of them in many endemic areas, the unambiguous detection of anti-DENV antibodies using currently available commercial kits, which use mixtures of inactivated virus preparations or recombinant envelope proteins for antibody detection, is often not possible .
Efforts to eliminate the problem of cross-reactivity have begun to focus on the utility of DENV envelope protein domain III (EDIII), as a diagnostic intermediate of high specificity [3–5]. As this domain contains both serotype-specific as well as DENV complex-specific epitopes , it is necessary to utilize EDIIIs of all four DENV serotypes to detect anti-DENV antibodies. Recently, we designed a single recombinant chimeric tetravalent antigen, EDIII-T, by linking the EDIIIs of the four DENV serotypes . However, the sensitivity of this antigen in detecting anti-DENV antibodies in enzyme linked immunosorbent assays (ELISA) was not as high as that of the reference assays. This may have been the result of unavailability of some of the epitopes, arising either from the incorporation of the EDIIIs into a tetravalent design, or, due to random adsorption of the EDIII-T antigen on the polystyrene surface during the performance of ELISAs. To address these issues we have expressed and purified four monovalent DENV EDIII antigens [7, 8] and a biotinylated version of EDIII-T antigen (b-EDIII-T) , for oriented immobilization on a streptavidin-coated surface.
The major aims of this study were to (i) compare the performance of single EDIII-T antigen with a physical mixture of monovalent EDIIIs corresponding to the four DENV serotypes; and, (ii) evaluate if oriented immobilization of the tetravalent antigen influences the sensitivity of detection of both IgG and IgM classes of anti-DENV antibodies, in indirect ELISA. We report here the outcome of a parallel evaluation of a physical mixture of EDIIIs, EDIII-T and b-EDIII-T as diagnostic antigens in ELISAs for the detection of anti-DENV antibodies in human sera.
A panel of 164 sera obtained from both dengue-endemic and non-endemic regions was pre-screened for evidence of infection by DENV, TBEV and a variety of non-flavivirus pathogens including Chikungunya virus, Plasmodium, Leptospira, and Salmonella using commercially available kits. This panel was used in indirect ELISAs to evaluate the performance of a mixture of monovalent EDIIIs, EDIII-T and b-EDIII-T as diagnostic reagents in detecting anti-DENV antibodies.
Goat anti-human IgG (γ-chain specific)-horseradish peroxidase (HRP), and goat anti-human IgM (μ-chain specific)-HRP conjugates were purchased from Calbiochem (La Jolla, CA, USA). HRP substrate 3, 3', 5, 5'-Tetramethylbenzidine (TMB) was from Sigma-Aldrich (St. Louis, MO, USA). Maxisorp polystyrene ELISA plates and immobilizer streptavidin ELISA plates were from Nunc-Thermo fisher scientific (Roskilde, Denmark). Dengue IgG/IgM capture ELISA test was from PanBio Diagnostics (Brisbane, Australia) and TBEV IgG/IgM ELISA was from Virion/Serion GmbH (Würzburg, Germany). The Advantage Pan Malaria Card test for Plasmodium LDH antigen and the Lepto IgM micro-ELISA test for Leptospira interrogans antibodies were from J. Mitra & Company Ltd. (New Delhi, India). The Typhi-Dot test for Salmonella typhi antibodies was from MBDr Diagnostics Sdn Bhd (Selangor, Malaysia) and the Insight Chik V rapid test for chikungunya antibodies was from Tulip Diagnostics Ltd. (Goa, India).
The human sera samples (n = 164) used in this study were from hospitals in India and Finland. Sera were drawn in the early symptomatic phase after informed written consent of the patients. Ethical permissions for the collection of blood samples were obtained from the ethical committees of the respective hospitals. All sera were pre-screened for anti-DENV antibodies using the PanBio Dengue IgG/IgM capture ELISA test. Eighty samples scored positive and 84 scored negative for DENV IgG whereas 81 samples scored positive and 83 scored negative for DENV IgM antibodies. Of the DENV IgM-/IgG- sera samples (n = 72), there was evidence of infection by TBEV (n = 18), Plasmodium (n = 6), Leptospira interrogans (n = 5), Salmonella typhi (n = 6) and Chikungunya virus (n = 4).
Recombinant EDIII antigens
The monovalent EDIIIs antigens used in this study, corresponding to the four DENV serotypes, each contain 121 amino acid (aa) residues spanning DENV envelope aa296-aa416. Their expression and purification have been reported earlier [7, 8]. The design of the tetravalent antigen EDIII-T containing the EDIIIs of the four DENV serotypes, linked in tandem, its expression and purification have been described previously . To produce the biotinylated tetravalent antigen b-EDIII-T, we used an in vivo method wherein the biotinyl moiety is added to a specific site enzymatically . The chemical method which tends to add the biotinyl moiety in a random fashion to available acceptor groups is not quite suitable for achieving uniform and oriented binding on streptavidin coated surfaces. In order to carry out site-specific enzymatic biotinylation of the EDIII-T antigen in vivo, a biotin acceptor peptide (BAP) was cloned in frame with the amino terminus of the EDIII-T antigen and co-expressed with biotin ligase in E. coli. The engineered BAP moiety of the recombinant tetravalent antigen serves as the substrate for biotin ligase resulting in the production of in vivo biotinylated tetravalent antigen, b-EDIII-T .
IgG and IgM indirect ELISA
Comparison of EDIII-based monovalent antigen mixture and single tetravalent antigen in anti-DENV antibody detection a
IgG (n = 80)
IgM (n = 81)
Mean Ratio of S/Co
values (95% CI)b
Mean Ratio of S/Co
values (95% CI)b
% Sensitivity c
% Specificity d
The performance of b-EDIII-T as a capture antigen in the detection of anti-DENV antibodies a
IgG (n = 80)
IgM (n = 81)
Mean Ratio of S/Co
values (95% CI)b
Mean Ratio of S/Co
values (95% CI)b
% Sensitivity c
% Specificity d
To compare the performance of the single tetravalent EDIII-T antigen with that of a mixture of the monovalent EDIII antigens in detecting anti-DENV antibodies, the S/Co values were used to calculate a ratio by dividing the S/Co value obtained using EDIII-T antigen by the S/Co value obtained using the EDIII monovalent antigen mixture. Similarly, the performance of b-EDIII-T in streptavidin-coated ELISA plates versus polystyrene plates was assessed from a ratio of the corresponding S/Co values. The significance of the relative sensitivity was assessed by obtaining the 95% confidence interval (CI) using an alpha value of 0.05, the calculated standard deviation and the sample size. Statistical calculations were performed using MS Excel 2003 software.
Comparison of EDIII antigen mixture versus a single chimeric EDIII-T antigen in indirect ELISAs
Determination of the effect of oriented immobilization of the tetravalent antigen in indirect ELISA
It has been suggested that specific immobilization of antigen on the ELISA plate well can improve the performance of the immunoassay compared to passive coating of antigen [9–11]. To test if this may be true for the detection of anti-DENV antibodies using the tetravalent antigen, we used a biotinylated version of this antigen to achieve specific and oriented immobilization on streptavidin treated ELISA plates. This demonstrated that, indeed, b-EDIII-T coated on streptavidin plates was superior in sensitivity in comparison to passively coated non-biotinylated EDIII-T antigen in detecting IgG as well as IgM antibodies (compare Figure 1B with 1D for IgG; and 1F with 1H for IgM; p < 0.05 in both cases). This enhancement in assay sensitivity was not evident if the b-EDIII-T antigen was passively coated on polystyrene plates (compare Figure 1B with 1C for IgG; and 1F with 1G for IgM). The data in Table 2 show that the use of b-EDIII-T coated on streptavidin can enhance the efficiency of detection of both IgG and IgM anti-DENV antibodies, as evidenced by 30% increase in the mean S/Co values.
This study was undertaken to investigate if the antigenic epitopes on the chimeric tetravalent EDIII-T antigen are available and accessible to anti-DENV antibodies. To this end, the ELISA reactivity of a physical mixture of the 4 EDIII antigens was compared to that of the EDIII-T antigen using a panel of 164 human sera that were pre-screened with a battery of commercially available tests for DENV, TBEV, Chikungunya virus, Plasmodium, Leptospira, and Salmonella. The lower specificity of the commercial Dengue IgG/IgM capture ELISA (PanBio Diagnostics), which served as a reference in this study, is well documented . An assessment of the true sensitivity of the EDIII-based assays described here was precluded due to non-availability of adequate sera for characterization by virus neutralization tests. However, this does not adversely affect the conclusions of this study as it compares the relative performance of the tetravalent EDIII-T antigen against a mixture of monovalent EDIIIs and evaluates the effect of using biotinylated versus non-biotinylated EDIII-T in detecting serum anti-DENV antibodies.
In both IgM and IgG indirect ELISAs the sensitivities manifested a small but significant improvement when the coating antigen was the single tetravalent antigen compared to the physical mixture of four EDIIIs (Table 1). Thus, this analysis showed that the individual EDIII components are well displayed in the EDIII-T antigen. We also found that biotinylation of the tetravalent antigen enhanced the efficiency of anti-DENV antibody detection further, by 30%, when it was immobilized on streptavidin-treated, but not on untreated surface. Further, this enhancement was statistically significant (Table 2). Additionally, the amount of biotinylated antigen (25 ng per well) required was a fraction of that of its non-biotinylated counterpart (300ng/well). This is presumably a reflection of better availability of the b-EDIII-T antigen stemming from its orderly and oriented immobilization through its biotinyl moiety to the streptavidin surface. This is consistent with the notion that passive, random coating on polystyrene surfaces offers only a small fraction of the antigen for interaction with antibodies .
Using b-EDIII-T coated on streptavidin surface, the sensitivity of the IgG-ELISAs was ~91% (Table 2). In the IgM assay, sera were pre-cleared with rheumatoid factor absorbents to eliminate possible IgG interference. Yet, sensitivity of IgM detection was consistently lower and the maximum that could be achieved was ~75% (Table 2). The observation that the results of EDIII-T based ELISAs were slightly better than those obtained with the mixture of EDIIIs argues against the possibility that the tetravalent design may have contributed to the lower sensitivity. A more likely possibility is that natural DENV infections generate a complex polyclonal response targeting a whole range of viral epitopes with EDIII-specific antibodies comprising only a small proportion of the total anti-DENV antibody population .
A recently reported comparative analysis of several commercial DENV IgM antibody ELISAs has shown that most of these suffer from low specificity, with sera from a large percentage of malaria- and leptospirosis-positive individuals scoring positive for anti-DENV IgM antibodies . To address the issue of false positives, we included in our study a collection of 39 DENV IgM-/IgG- sera that were positive for infection by several other pathogens such as Plasmodium, Leptospira, Salmonella, TBEV and Chikungunya virus. Regardless of whether we used EDIII monovalent antigen mixture or either version of the tetravalent antigen, all these 39 sera were scored as negative samples in both IgM and IgG ELISAs (Figure 1). The level of observed specificity may stem from the EDIII epitopes predominantly recognizing the DENV complex, thereby reducing cross reactivity from antibodies elicited by other non-DENV pathogens.
The multiepitope antigen design coupled with the requirement of very low quantity per assay has potential cost benefit. However, the sensitivity needs to be enhanced further, presumably by the inclusion of additional DENV specific epitopes. The EDIII based ELISAs may be useful in epidemiological surveillance and vaccine efficacy trials.
List of abbreviations
Envelope domain III
Enzyme-linked immunosorbent assay
Tick-borne encephalitis virus
3, 3', 5, 5'-Tetramethylbenzidine.
Authors thank Dr. Amita Agarwal from Sanjay Gandhi Post Graduate Institute, Lucknow, India and Dr. Raija Vainionpää from the Department of Virology, University of Turku, Turku, Finland, for providing human sera samples. This work was supported by a grant from the Department of Biotechnology, Govt. of India.
- Gubler DJ, Kuno G, Markoff L: Flaviviruses. Fields Virology. Edited by: Knipe DM, Howley PM. 2007, Philadelphia, Wolters Kluwer and Lippincott Williams & Wilkins, 1153-252. 5Google Scholar
- Swaminathan S, Khanna N: Dengue: recent advances in biology and current status of translational research. Curr Mol Med. 2009, 9: 152-173. 10.2174/156652409787581592.View ArticlePubMedGoogle Scholar
- Simmons M, Porter KR, Escamilla J, Graham R, Watts DM, Eckels KH, Hayes CG: Evaluation of recombinant dengue viral envelope B domain protein antigens for the detection of dengue complex-specific antibodies. Am J Trop Med Hyg. 1998, 58: 144-151.PubMedGoogle Scholar
- Ludolfs D, Schilling S, Altenschmidt J, Schmitz H: Serological differentiation of infections with dengue virus serotypes 1 to 4 using recombinant antigens. J Clin Microbiol. 2002, 40: 4317-4320. 10.1128/JCM.40.11.4317-4320.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- Hapugoda MD, Batra G, Abeyewickreme W, Swaminathan S, Khanna N: Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes. Clin Vac Immunol. 2007, 14: 1505-1514. 10.1128/CVI.00145-07.View ArticleGoogle Scholar
- Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillén G: Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines. 2010, 9: 137-147. 10.1586/erv.09.139.View ArticlePubMedGoogle Scholar
- Khanam S, Etemad B, Khanna N, Swaminathan S: Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am J Trop Med Hyg. 2006, 74: 266-277.PubMedGoogle Scholar
- Batra G, Talha SM, Nemani SK, Dhar N, Swaminathan S, Khanna N: Expression, purification and characterization of in vivo biotinylated dengue virus envelope domain III based tetravalent antigen. Prot Exp Purif. 2010, 74: 99-105. 10.1016/j.pep.2010.04.017.View ArticleGoogle Scholar
- Schetters H: Avidin and streptavidin in clinical diagnostics. Biomol Eng. 1999, 16: 73-78. 10.1016/S1050-3862(99)00034-0.View ArticlePubMedGoogle Scholar
- Butler JE: Solid supports in enzyme-linked immunosorbent assay and other solid-phase immunoassays. Methods. 2000, 22: 4-23. 10.1006/meth.2000.1031.View ArticlePubMedGoogle Scholar
- Nakanishi K, Sakiyama T, Kumada Y, Imamura K, Imanaka H: Recent advances in controlled immobilization of proteins onto the surface of the solid substrate and its possible application to proteomics. Curr Proteomics. 2008, 5: 161-175. 10.2174/157016408785909622.View ArticleGoogle Scholar
- Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, Pelegrino JL, Vázquez S, Artsob H, Drebot M, Gubler DJ, Halstead SB, Guzmán MG, Margolis HS, Nathanson CM, Lic NRR, Bessoff KE, Kliks S, Peeling RW: Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis. 2009, 15: 436-440. 10.3201/eid1503.080923.View ArticlePubMedPubMed CentralGoogle Scholar
- Wahala WMPB, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM: Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009, 392: 103-113. 10.1016/j.virol.2009.06.037.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/11/64/prepub